You can bring a Medtronic bladder stimulator lawsuit, but these cases face a legal barrier most device claims don’t. Because the InterStim system received the FDA’s most rigorous approval, a 2008 Supreme Court decision blocks most traditional product liability theories. What remains is a narrow lane: claims that mirror a specific federal safety requirement Medtronic allegedly violated. Courts have already thrown out InterStim complaints that missed that mark.
Why Preemption Is the First Hurdle
The InterStim went through the FDA’s Premarket Approval (PMA) process, the agency’s most extensive review pathway for high-risk devices.1U.S. Food and Drug Administration. Premarket Approval (PMA) – InterStim P970004 That approval matters far beyond the FDA. Under 21 U.S.C. ยง 360k, states cannot impose device requirements “different from, or in addition to” federal ones that relate to safety or effectiveness.2Office of the Law Revision Counsel. 21 USC 360k – State and Local Requirements Respecting Devices
In Riegel v. Medtronic, Inc., the Supreme Court held that state common-law claims count as “requirements” under that statute. Because PMA approval already imposes federal requirements on design, labeling, and manufacturing, ordinary negligence and strict liability theories challenging a PMA device are preempted.3Justia U.S. Supreme Court Center. Riegel v Medtronic Inc
In practice, you generally cannot sue Medtronic by arguing the InterStim was poorly designed, should have carried stronger warnings, or was unreasonably dangerous. Devices cleared through the lighter 510(k) pathway don’t get this shield, but InterStim isn’t one of them.
The Parallel Claim: What Still Works
Preemption doesn’t seal the courthouse doors. The Court left open claims that are “parallel” to federal requirements rather than different from or additional to them. A parallel claim argues that Medtronic violated an existing FDA regulation and that the same violation gives rise to state-law liability.3Justia U.S. Supreme Court Center. Riegel v Medtronic Inc
Courts hold these claims to a high pleading standard. In Halyckyj v. Medtronic, Inc., a federal judge in Michigan dismissed the plaintiff’s 2024 InterStim complaint because it didn’t identify with enough specificity which federal requirements Medtronic allegedly violated or how. The court gave the plaintiff 30 days to amend.4GovInfo. Case 2:24-cv-10691 Halyckyj v Medtronic Inc The lesson: vague pleadings lose on a motion to dismiss, no matter how real the injury.
Viable parallel claims against Medtronic tend to fall into three categories.
Failure to report adverse events. Manufacturers must report device malfunctions, serious injuries, and deaths to the FDA within 30 calendar days of learning of them. If Medtronic knew about a pattern of complications and didn’t file timely reports, that’s a federal violation that can anchor a state-law claim.5eCFR. 21 CFR Part 803 – Medical Device Reporting
Manufacturing deviations. If a specific unit was made in a way that departed from the specifications approved during PMA, the claim doesn’t attack the approved design; it attacks the failure to follow it.
Labeling violations. If Medtronic changed labeling or instructions without required FDA approval, or omitted warnings the FDA specifically mandated, that parallels a federal duty.
Building any of these requires detailed evidence of what Medtronic knew, when, and which regulations it allegedly broke. Most of that evidence lives in internal company documents obtained through discovery, which makes these cases expensive to pursue.
Recalls and Reports That Strengthen a Claim
FDA recall records are useful evidence because each one documents a defect the agency confirmed and puts the manufacturer’s knowledge into the public record. Several Class 2 recalls have hit InterStim-related products recently:
- April 2025: Medtronic recalled InterStim evaluation handsets that couldn’t communicate with the neurostimulator due to a processing speed mismatch. The FDA identified device design as the cause. Patients could experience a return of overactive bladder, urinary retention, or fecal incontinence symptoms if therapy stopped.6U.S. Food and Drug Administration. Class 2 Device Recall InterStim – Z-1704-2025
- September 2024: The wireless recharger used with the InterStim Micro (Model 97810) was recalled because it could fail to establish a charging session on first use, potentially leaving the implanted stimulator without power.7U.S. Food and Drug Administration. Class 2 Device Recall Medtronic Wireless Recharger
- June 2024: A pairing handset recall involved units that couldn’t complete pairing with the communicator during setup.8U.S. Food and Drug Administration. Class 2 Device Recall Medtronic InterStim – Z-0372-2025
If your injury involves a recalled component, or a defect that resembles a recalled issue, the recall bolsters the argument that Medtronic knew about the problem. Design-related recalls tend to be more useful than one-off manufacturing errors because they point to systemic issues.
Individual adverse event reports in the FDA’s MAUDE database can also matter. One InterStim II report described a patient with involuntary leg and foot movements, electrical shocks, and constant burning and throbbing at the implant site; after removal, the patient reported lasting nerve damage, chronic pain, and persistent lower back and hip pain. The FDA classified the outcome as involving required intervention and disability.9U.S. Food & Drug Administration. MAUDE Adverse Event Report – Medtronic InterStim II Evidence that Medtronic received similar complaints but delayed reporting or responding could form the backbone of a parallel claim.5eCFR. 21 CFR Part 803 – Medical Device Reporting
Which InterStim Injuries Actually Support a Case
Not every complication translates into a viable lawsuit. Reoperation is common with these devices: one study found an overall reoperation rate of 28.1%, driven mainly by device malfunction (about 34% of reoperations), infection (about 22%), device-related pain (about 15%), and battery replacement (about 14%).10International Continence Society. Reoperation Rates in Patients With InterStim Therapy Lead migration, where the electrode shifts from its intended position, has been documented in up to roughly 12% of patients and can cause loss of therapeutic effect or new pain radiating down the leg.11PMC (NCBI). Troubleshooting InterStim Sacral Neuromodulation Generators to Recover Function
The strongest cases share a few features:
- A documented device malfunction or complication that fits a known pattern, especially one tied to a recall.
- Medical records showing the complication required additional surgery or caused lasting harm.
- Facts suggesting Medtronic may have known about the risk but failed to meet FDA reporting or manufacturing requirements.
A case is weaker when the harm reflects a known and adequately disclosed risk of sacral neuromodulation, when the device worked as designed but the patient simply didn’t respond, or when the complaint cannot point to a specific federal violation.
Filing Deadlines
Every state sets its own statute of limitations for product liability. The window is typically two to four years, sometimes as short as one year and sometimes as long as six. Most states start the clock when the injury is discovered or reasonably should have been discovered, not on the date of implant. That “discovery rule” matters here because complications like gradual nerve damage or slow lead migration may not become obvious until well after surgery.
Roughly 19 states also impose a statute of repose, an absolute outer deadline regardless of when the injury appeared. These range from about 5 to 20 years after the product’s first sale. A statute of repose can bar a claim even if you just discovered the injury, so the state-specific deadline needs checking early.
The clock can pause in narrow circumstances. If the injured person is a minor, the deadline may not start until adulthood. If a manufacturer actively concealed a known defect, some states allow additional time. These exceptions are fact-specific.
What Compensation Covers
If a claim survives preemption, the recoverable damages resemble other product liability cases. Economic damages cover medical bills for revision or removal surgery and ongoing treatment, lost income during recovery or from disability, and out-of-pocket costs like travel to specialists. Given how often InterStim complications require follow-up surgery, medical expenses alone can be substantial.
Non-economic damages compensate for pain, suffering, and diminished quality of life. Patients with chronic nerve damage or lasting pain after removal often have significant non-economic claims. Punitive damages, meant to punish reckless conduct, are possible but depend on the evidence of what Medtronic knew and when, and the standard varies by state.
Most attorneys handling device cases work on contingency, taking a percentage of any recovery rather than charging hourly. Consultations under that model are typically free.
The State of InterStim Litigation Now
There is no centralized Multi-District Litigation for InterStim claims as of early 2026. Cases proceed individually in federal court. Halyckyj v. Medtronic in Michigan’s Eastern District, dismissed on preemption grounds in December 2024 with leave to amend, is the most visible recent example.4GovInfo. Case 2:24-cv-10691 Halyckyj v Medtronic Inc Without an MDL, each plaintiff carries the full cost of litigation, but cases aren’t held up by consolidated proceedings either. If filings pick up, the Judicial Panel on Multidistrict Litigation or either party could push for consolidation.
For anyone weighing a claim, the immediate steps are preserving medical records and any communications with the medical team about device problems, and contacting a medical device attorney before the statute of limitations becomes an issue. The preemption bar is real, but so is the parallel-claim path, and the difference between a case that gets dismissed and one that reaches discovery often comes down to how precisely the federal violation is pleaded at the start.